NurExone Biologic (FRA:J90) Current Deferred Taxes Liabilities : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

NurExone Biologic's current deferred tax liabilities for the quarter that ended in Mar. 2025 was €0.00 Mil.

NurExone Biologic Current Deferred Taxes Liabilities Historical Data

The historical data trend for NurExone Biologic's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Current Deferred Taxes Liabilities Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Current Deferred Taxes Liabilities

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial											-	-	-	-	-

NurExone Biologic Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

NRXBF:USA NRX:Canada

Address

1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines